Growth Forecast for Hepatic Sarcopenia Nutrition Market Through 2036

The demand for hepatic sarcopenia nutrition is driven by rising concerns over poor appetite and early satiety among patients, necessitating nutrition solutions that deliver protein without requiring large meals. High-protein oral nutritional supplements (ONS) and late-evening formulations are becoming essential when food intake is insufficient. The May 2025 guidelines from the American College of Gastroenterology emphasize the need for adequate protein intake, late-evening carbohydrate consumption, and plant-based or BCAA-enriched protein sources.

While the market is expanding, variations in muscle health screening and follow-up care across countries affect adoption rates. Japan is predicted to grow at a CAGR of 9.7% from 2026 to 2036 with enhancements in muscle-health assessments for adults aged 50 to 64, while South Korea is estimated to grow at 9.4%. A study in South Korea in 2026 revealed that 35.8% of cirrhosis patients were at high nutritional risk.

The market value projections include:

- 2025: USD 130.2 million (actual)

- 2026: USD 142.2 million (estimate)

- 2036: USD 342.8 million (forecast)

In 2026, BCAA-enriched high-protein ONS is expected to hold a substantial share of 41.5% due to the specific protein needs of liver patients. Compensated cirrhosis is anticipated to represent about 55.3% of the market, as nutrition support can be initiated prior to any severe decompensation affecting food intake.

The ready-to-drink (RTD) product form is expected to lead with a 38.2% share in 2026, valued for its ease of preparation and consumption. Homecare is projected to hold a significant 42.9% share as nutritional needs often extend beyond hospital stays.

Key companies in this sector include Otsuka Pharmaceutical, Abbott, Nestle Health Science, Danone Nutricia, Ajinomoto, Meiji Holdings, Fresenius Kabi, and Medtrition, focusing on tailored nutrition solutions to meet the specific needs of patients with liver-related sarcopenia.